Daniel Obrecht
YOU?
Author Swipe
View article: Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae
Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae Open
The rise of antimicrobial resistance poses a substantial threat to our health system, and, hence, development of drugs against novel targets is urgently needed. The natural peptide thanatin kills Gram-negative bacteria by targeting protein…
View article: Antibiotic polymyxin arranges lipopolysaccharide into crystalline structures to solidify the bacterial membrane
Antibiotic polymyxin arranges lipopolysaccharide into crystalline structures to solidify the bacterial membrane Open
Polymyxins are last-resort antibiotics with potent activity against multi-drug resistant pathogens. They interact with lipopolysaccharide (LPS) in bacterial membranes, but mechanistic details at the molecular level remain unclear. Here, we…
View article: Novel Class of Antibiotics Disassembles the Lipopolysaccharide Transport Bridge
Novel Class of Antibiotics Disassembles the Lipopolysaccharide Transport Bridge Open
The rapid rise of multi-resistant bacteria poses a significant threat to our health system. The development of drugs against novel targets is urgently needed to replenish the clinical arsenal with effective antibiotics. The naturally occur…
View article: Macrocycle Therapeutics to Treat Life-threatening Diseases
Macrocycle Therapeutics to Treat Life-threatening Diseases Open
Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CX…
View article: Anti-biofilm activity of murepavadin against cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates
Anti-biofilm activity of murepavadin against cystic fibrosis <i>Pseudomonas aeruginosa</i> isolates Open
Objectives To determine the activity of murepavadin in comparison with tobramycin, colistin and aztreonam, against cystic fibrosis (CF) Pseudomonas aeruginosa isolates growing in biofilms. The biofilm-epidemiological cut-off (ECOFF) values…
View article: Identification of Genes Required for Resistance to Peptidomimetic Antibiotics by Transposon Sequencing
Identification of Genes Required for Resistance to Peptidomimetic Antibiotics by Transposon Sequencing Open
Pseudomonas aeruginosa is an opportunistic human pathogen and a leading cause of nosocomial infections. Due to its high intrinsic and adaptive resistance to antibiotics, infections caused by this organism are difficult to treat and new the…
View article: Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models
Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models Open
Murepavadin (POL7080) represents the first member of a novel class of outer membrane protein-targeting antibiotics. It specifically interacts with LptD and inhibits lipopolysaccharide (LPS) transport.
View article: Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide
Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide Open
Background: Balixafortide is a very potent, well tolerated and highly selective next generation CXCR4 antagonist derived over the past decade through multiple rounds of optimization starting from the natural product polyphemusin. Clinical …
View article: Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia
Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia Open
The clinical development of antibiotics with a new mode of action combined with efficient pulmonary drug delivery is a priority against untreatable Pseudomonas aeruginosa lung infections. POL7001 is a macrocycle antibiotic belonging to the…